Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own BioCryst Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Janus Global Life Sciences Fund
4,067,864
3.72%
663,284
0.72%
06/30/2018
Fidelity Select Biotechnology Portfolio
3,287,837
3.01%
0
0.26%
07/31/2018
Vanguard Total Stock Market Index Fund
2,407,403
2.2%
0
0%
07/31/2018
Prudential Jennison Health Sciences Fund
2,128,278
1.95%
0
0.6%
07/31/2018
iShares Russell 2000 ETF
2,081,262
1.9%
-1,113
0.03%
09/06/2018
SPDR S&P Biotech ETF
2,061,064
1.88%
5,304
0.25%
09/06/2018
Janus Capital Funds Plc - Global Life Sciences Fund
1,591,251
1.46%
1,591,251
0.45%
12/31/2017
Vanguard Extended Market Index Fund
1,348,594
1.23%
0
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,264,515
1.15%
-16,527
0.09%
09/06/2018
Janus Contrarian Fund
1,036,889
0.95%
1,036,889
0.27%
06/30/2018

About BioCryst Pharmaceuticals

View Profile
Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.